Effects of scopolamine on forced swimming behavior in rats and its possible action target

doi:10.3969/j.issn.1006-7795.2018.05.002

Abstract

Abstract: Objective To clarify the possible brain regions and targets to mediate antidepressant-like effects of scopolamine. Methods Sprague Dawley (SD) rats were randomly divided into scopolamine group and saline control group. The rats were intraperitoneally injected with scopolamine or equal volume saline. After 24 hours, open field test and forced swimming test were carried out to evaluate the effect of scopolamine on the behavior of rats. γ-Aminobutyric acid-A (GABA-A) receptor agonist Muscimol (1.25 μg)was stereotaxically injected into the medial prefrontal cortex (mPFC) of rats one hour before intraperitoneal injection of 25 μg/kg scopolamine. Behavioral effects were examined after 24 hours. 0.5 μg, 1 μg and 2 μg muscarinic acetylcholine receptor 2 (M₂) receptor selective antagonist methoctramine (MCT) were respectively injected into the lateral ventricle of rats by the micro dosing system, while the control group was given 2 μL saline. Behavioral effects were examined after 24 hours. Results After 24 hours of intraperitoneal injection of scopolamine, the immobility time in rats was lower than that in the control group (P<0.05), while no statistical difference was observed in the total distance of the open field (P>0.05). In Muscimol+scopolamine group, the immobility time in rats was significantly higher than that in scopolamine group (P<0.01). No statistical difference was observed in the total distance in the open field test (P>0.05). Compared with lateral ventricle injection of saline, 0.5 μg MCT had no effect on the immobility time (P>0.05), 1 μg MCT could significantly reduce the immobility time (P<0.01), whereas 2 μg MCT could significantly increase the immobility time (P<0.05). Conclusion Scopolamine may exert antidepressant-like effects by blocking the M₂ receptor of mPFC.

Key words: depression, scopolamine, muscarinic acetylcholine receptor, forced swimming test

CLC Number:

R749.4

Shi Dandan, Yang Jian, Zhang Jinniu, Wang Gang. Effects of scopolamine on forced swimming behavior in rats and its possible action target[J]. Journal of Capital Medical University, 2018, 39(5): 630-635.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.05.002

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I5/630

References

[1] Friedrich M J. Depression is the leading cause of disability around the world[J]. JAMA, 2017, 317(15):1517.
[2] Trivedi M H, Rush A J, Wisniewski S R, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:implications for clinical practice[J]. Am J Psychiatr, 2006, 163(1):28-40.
[3] 王刚. 抗抑郁药的起效时间[J]. 中华精神科杂志,2011(1):49-50.
[4] Furey M L, Drevets W C. Antidepressant efficacy of the antimuscarinic drug scopolamine:a randomized, placebo-controlled clinical trial[J]. Arch Gen Psychiatr, 2006, 63(10):1121-1129.
[5] Gillin J C, Sutton L, Ruiz C, et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group[J]. Biol Psychiatr, 1991, 30(2):157-169.
[6] Gibbons A S, Jeon W J, Scarr E, et al. Changes in muscarinic M2 receptor levels in the cortex of subjects with bipolar disorder and major depressive disorder and in rats after treatment with mood stabilisers and antidepressants[J]. Int J Neuropsychopharmacol, 2016, 19(4).
[7] Gibbons A S, Scarr E, McLean C, et al. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects[J]. J Affect Disord, 2009, 116(3):184-191.
[8] Comings D E, Wu S, Rostamkhani M, et al. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women[J]. Am J Med Genet, 2002, 114(5):527-529.
[9] Wang J C, Hinrichs A L, Stock H, et al. Evidence of common and specific genetic effects:association of the muscarinic acetylcholine receptor M2(CHRM2) gene with alcohol dependence and major depressive syndrome[J]. Hum Mol Genet, 2004, 13(17):1903-1911.
[10] Drevets W C, Price J L, Furey M L. Brain structural and functional abnormalities in mood disorders:implications for neurocircuitry models of depression[J]. Brain Struct Funct, 2008, 213(1-2):93-118.
[11] MacQueen G M, Yucel K, Taylor V H, et al. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder[J]. Biol Psychiatry, 2008, 64(10):880-883.
[12] Li N, Lee B, Liu R J, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists[J]. Science, 2010, 329(5994):959-964.
[13] Navarria A, Wohleb E S, Voleti B, et al. Rapid antidepressant actions of scopolamine:Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors[J]. Neurobiol Dis, 2015, 82:254-261.
[14] Witkin J M, Overshiner C, Li X, et al. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine[J]. J Pharmacol Exp Ther, 2014, 351(2):448-456.
[15] Chau D T, Rada P, Kosloff R A, et al. Nucleus accumbens muscarinic receptors in the control of behavioral depression:antidepressant-like effects of local M1 antagonist in the Porsolt swim test[J]. Neuroscience, 2001, 104(3):791-798.
[16] Dong J, Zhou Q, Wei Z, et al. Protein kinase A mediates scopolamine-induced mTOR activation and an antidepressant response[J]. J Affect Disord, 2018, 227:633-642.
[17] Lucas-Meunier E, Fossier P, Baux G, et al. Cholinergic modulation of the cortical neuronal network[J]. Pflugers Arch, 2003, 446(1):17-29.
[18] Medalla M, Barbas H. The anterior cingulate cortex may enhance inhibition of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic sites[J]. J Neurosci, 2012, 32(44):15611-15625.
[19] Voleti B, Navarria A, Liu R J, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses[J]. Biol Psychiatry, 2013, 74(10):742-749.
[20] Chen Z, Huang C, Ding W. Z-Guggulsterone improves the scopolamine-induced memory impairments through enhancement of the BDNF signal in C57BL/6J Mice[J]. Neurochem Res, 2016, 41(12):3322-3332.
[21] Park H R, Lee H, Park H, et al. Fermented sipjeondaebo-tang alleviates memory deficits and loss of hippocampal neurogenesis in scopolamine-induced amnesia in mice[J]. Sci Rep, 2016, 6:22405.
[22] Yu H, Li M, Shen X, et al. The requirement of L-Type voltage-dependent calcium channel (L-VDCC) in the rapid-acting antidepressant-like effects of scopolamine in mice[J]. Int J Neuropsychopharmacol, 2018, 21(2):175-186.
[23] Bhattacharya S K, Sen A P. Effects of muscarinic receptor agonists and antagonists on swim-stress-induced ‘behavioural despair’ in rats[J]. J Psychopharmacol, 1991, 5(1):77-81.